Jennifer Leigh Clarke
Neurosurgery · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 5
- Since medical school
- 24 years
- University of California, San Francisco School of Medicine, 2002
Offices
5 locations · UCSF Medical Group Business Services · University of California San Francisco
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Jennifer Leigh Clarke’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A85636 · Current
Licensed to practise in California · since 2004 · expires 2027-08-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$22,457
Medicare paid this office $22,457 for 80 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 48 | $12,369 | $120 |
| Return visit (30+ min) | 27 | $2,913 | $86 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 57 | $1,552 | $15 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | $473 | $28 |
Who their Medicare patients are
80 Original Medicare patients in 2024. Average age 64 · Under 65 35% · 85 and older 0% · Women 34% · Also on Medicaid 25% · Health risk score 1.43. At or below the middle of the specialty; the typical neurosurgery clinician is at 1.46.
Conditions among them: High blood pressure 46% · Depression 28% · Stroke 18% · Diabetes 15%.
The office billed $143,298, Medicare allowed $29,353 and paid $22,457; for 329 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 80 | 329 | 64 | 1.43 | $143,298 | $22,457 |
| 2023 | 61 | 110 | 61 | 1.35 | $69,212 | $9,783 |
| 2022 | 87 | 646 | 61 | 1.53 | $295,865 | $33,668 |
| 2021 | 80 | 295 | 60 | 1.24 | $172,714 | $26,442 |
| 2020 | 67 | 148 | 59 | 1.35 | $105,852 | $13,696 |
| 2019 | 64 | 130 | 59 | 1.62 | $92,544 | $11,276 |
| 2018 | 79 | 178 | 62 | 1.31 | $121,165 | $15,974 |
| 2017 | 62 | 163 | 61 | 1.47 | $106,804 | $15,705 |
| 2016 | 63 | 187 | 62 | 1.29 | $119,519 | $17,612 |
| 2015 | 55 | 161 | 60 | 1.45 | $97,736 | $13,960 |
| 2014 | 66 | 171 | 63 | 1.42 | $86,204 | $12,108 |
| 2013 | 64 | 179 | 62 | 1.10 | $91,336 | $13,650 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 41 | $6,381 | $110 |
| Return visit (30+ min) | 14 | $1,158 | $72 |
| Short return visit (20+ min) | 11 | $593 | $46 |
2022: 5 services
| Long return visit (40+ min) | 52 | $13,059 | $114 |
| Return visit (30+ min) | 30 | $2,778 | $73 |
| Extended patient service without direct patient contact, first hour | 12 | $1,377 | $98 |
| Short return visit (20+ min) | 20 | $1,230 | $49 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $737 | $27 |
2021: 3 services
| Long return visit (40+ min) | 60 | $15,377 | $125 |
| Return visit (30+ min) | 19 | $2,190 | $73 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $849 | $29 |
2020: 2 services
| Long return visit (40+ min) | 45 | $8,797 | $98 |
| Return visit (30+ min) | 24 | $2,175 | $66 |
2019: 2 services
| Long return visit (40+ min) | 36 | $7,282 | $96 |
| Return visit (30+ min) | 28 | $2,083 | $56 |
2018: 2 services
| Long return visit (40+ min) | 46 | $9,961 | $95 |
| Return visit (30+ min) | 34 | $2,741 | $61 |
2017: 2 services
| Long return visit (40+ min) | 39 | $9,202 | $97 |
| Return visit (30+ min) | 24 | $2,383 | $66 |
2016: 3 services
| Long return visit (40+ min) | 40 | $9,599 | $97 |
| Return visit (30+ min) | 30 | $2,802 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,975 | $180 |
2015: 3 services
| Long return visit (40+ min) | 31 | $6,783 | $97 |
| Return visit (30+ min) | 26 | $3,102 | $66 |
| Short return visit (20+ min) | 13 | $632 | $40 |
2014: 3 services
| Long return visit (40+ min) | 25 | $3,092 | $91 |
| Return visit (30+ min) | 24 | $2,950 | $66 |
| Short return visit (20+ min) | 26 | $2,262 | $43 |
2013: 4 services
| Long return visit (40+ min) | 31 | $5,733 | $92 |
| Return visit (30+ min) | 33 | $3,865 | $67 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,138 | $88 |
| Short return visit (20+ min) | 15 | $1,070 | $43 |
Drugs they prescribed that Part D paid
$628,896
Pharmacies billed $628,896 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
104 generic and 36 brand-name prescriptions · $628,896 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tibsovo | 17 | $518,133 | $30,478 |
| Levetiracetam | 24 | $810 | $34 |
| Dexamethasone | 21 | $798 | $38 |
| Sumatriptan | 11 | $130 | $12 |
Year by year
| 2024 | 140 | 34 | None | 26% | $628,896 |
| 2023 | 146 | 27 | 0% (0) | 9% | $185,830 |
| 2022 | 176 | 40 | None | 7% | $22,768 |
| 2021 | 155 | 31 | None | 8% | $17,058 |
| 2020 | 126 | 22 | 0% (0) | None | $11,549 |
| 2019 | 123 | 31 | None | 9% | $14,486 |
| 2018 | 167 | 33 | None | None | $5,239 |
| 2017 | 120 | 27 | 0% (0) | None | $17,094 |
| 2016 | 148 | 27 | 0% (0) | 12% | $8,705 |
| 2015 | 129 | 27 | None | 25% | $13,830 |
| 2014 | 193 | 28 | None | 21% | $21,251 |
| 2013 | 139 | 23 | None | None | $21,131 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Levetiracetam | 32 | $1,718 | $54 |
| Oxcarbazepine | 15 | $638 | $43 |
| Sertraline | 14 | $183 | $13 |
2022: 4 drugs
| Levetiracetam | 43 | $2,281 | $53 |
| Dexamethasone | 25 | $728 | $29 |
| Ondansetron | 17 | $364 | $21 |
| Sertraline | 17 | $132 | $8 |
2021: 4 drugs
| Levetiracetam | 43 | $2,169 | $50 |
| Dexamethasone | 20 | $610 | $31 |
| Ondansetron | 17 | $497 | $29 |
| Sertraline | 11 | $14 | $1 |
2020: 3 drugs
| Levetiracetam | 35 | $1,489 | $43 |
| Dexamethasone | 21 | $565 | $27 |
| Ondansetron | 13 | $192 | $15 |
2019: 3 drugs
| Levetiracetam | 52 | $1,391 | $27 |
| Dexamethasone | 20 | $499 | $25 |
| Lamotrigine | 15 | $191 | $13 |
2018: 3 drugs
| Levetiracetam | 54 | $1,222 | $23 |
| Dexamethasone | 31 | $511 | $16 |
| Lamotrigine | 21 | $309 | $15 |
2017: 3 drugs
| Levetiracetam | 31 | $603 | $19 |
| Dexamethasone | 34 | $602 | $18 |
| Lamotrigine | 13 | $146 | $11 |
2016: 6 drugs
| Gleostine | 17 | $5,849 | $344 |
| Levetiracetam | 35 | $783 | $22 |
| Dexamethasone | 22 | $697 | $32 |
| Ondansetron | 12 | $190 | $16 |
| Sulfamethoxazole-Trimethoprim | 12 | $61 | $5 |
| Lorazepam | 11 | $29 | $3 |
2015: 5 drugs
| Vimpat | 14 | $9,486 | $678 |
| Dexamethasone | 20 | $664 | $33 |
| Levetiracetam | 33 | $615 | $19 |
| Lomustine | 12 | $592 | $49 |
| Ondansetron | 12 | $158 | $13 |
2014: 5 drugs
| Vimpat | 13 | $7,832 | $602 |
| Levetiracetam | 45 | $1,322 | $29 |
| Dexamethasone | 33 | $644 | $20 |
| Lorazepam | 19 | $83 | $4 |
| Ondansetron | 11 | $73 | $7 |
2013: 6 drugs
| Keppra | 24 | $14,173 | $591 |
| Divalproex Sodium Er | 13 | $1,995 | $153 |
| Levetiracetam | 27 | $943 | $35 |
| Dexamethasone | 14 | $440 | $31 |
| Ondansetron | 11 | $229 | $21 |
| Lorazepam | 17 | $82 | $5 |
Money from drug and device companies
$15,491 in 2024
| 2024 | 2 | 8 | $13,695 | $15,491 |
| 2022 | 2 | 2 | $2,640 | $2,754 |
| 2021 | 1 | 2 | $2,165 | $2,165 |
| 2020 | 1 | 2 | $2,350 | $2,350 |
| 2019 | 1 | 5 | $3,645 | $3,830 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Servier Pharmaceuticals | None | $15,294 | 7 payments
|
| Servier BioInnovation | None | $197 | 1 payment
|
See all 8 published payments
| Servier Pharmaceuticals | Meals · 2024-12-09 | None | $30 |
| Servier Pharmaceuticals | Travel · 2024-12-09 | None | $190 |
| Servier BioInnovation | Meals · 2024-11-20 | None | $197 |
| Servier Pharmaceuticals | Consulting · 2024-10-07 | None | $13,695 |
| Servier Pharmaceuticals | Meals · 2024-09-20 | None | $139 |
| Servier Pharmaceuticals | Meals · 2024-09-20 | None | $942 |
| Servier Pharmaceuticals | Meals · 2024-09-20 | None | $193 |
| Servier Pharmaceuticals | Meals · 2024-09-19 | None | $105 |
See earlier years (2022, 2021, 2020, 2019)
2022: $2,754
| Servier Pharmaceuticals | Tibsovo | $2,640 | 1 payment
|
| Servier BioInnovation | None | $114 | 1 payment
|
2021: $2,165
| Servier Pharmaceuticals | Tibsovo | $2,165 | 2 payments
|
2020: $2,350
| Agios Pharmaceuticals | Tibsovo | $2,350 | 2 payments
|
2019: $3,830
| Agios Pharmaceuticals | Tibsovo | $3,830 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Servier BioInnovation · Study of Ag-120 and Ag-881 in Subjects With Low Grade Glioma · 2024 | Their institution | $1,898,331 |
| Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2024 | Their institution | $959,255 |
| Servier BioInnovation · Phase 1 Astrocytoma Study Which Is A Study Looking at the Combination of Vorasidenib and Pembrolizumab · 2024 | Their institution | $824,791 |
| Novartis Pharmaceuticals Corporation · Pi3k Mtor Pathway Activation Stratified Phase II Study of Everolimus Afinitor Rad001 With and Without Temozolomide Temodar in the Treatment of Adult Patients With Supratentorial Low Grade Glioma · 2019 | Their institution | $378,125 |
| Servier Pharmaceuticals LLC · Study of Vorasidenib (Ag-881) in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation (Indigo) · 2021 | Their institution | $235,341 |
| Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2023 | Their institution | $123,074 |
| Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2025 | Their institution | $92,909 |
| Servier BioInnovation · Phase 1 Astrocytoma Study Which Is A Study Looking at the Combination of Vorasidenib and Pembrolizumab · 2023 | Their institution | $90,385 |
| Servier Pharmaceuticals LLC · Study of Orally Administered Ag-881 in Patients With Advanced Solid Tumors, Including Gliomas, With An Idh1 and/Or Idh2 Mutation · 2021 | Their institution | $87,280 |
| Servier BioInnovation · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Ag-881 in Subjects With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation · 2024 | Their institution | $78,446 |
| Servier BioInnovation · Phase 1 Astrocytoma Study Which Is A Study Looking at the Combination of Vorasidenib and Pembrolizumab · 2025 | Their institution | $72,130 |
| Merck Sharp & Dohme LLC · A Phase 1, Safety Lead-in and Randomized, Open-Label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent Or Progressive Enhancing Idh-1 Mutant Astrocytomas · 2023 | Their institution | $54,400 |
| Merck Sharp & Dohme LLC · A Phase 1, Safety Lead-in and Randomized, Open-Label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent Or Progressive Enhancing Idh-1 Mutant Astrocytomas · 2024 | Their institution | $35,500 |
| Agios Pharmaceuticals, Inc. · A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-881 in Patients With Advanced Hematologic Malignancies With An Idh1 Andor Idh2 Mutation · 2019 | Their institution | $33,602 |
| Merck Sharp & Dohme LLC · Open-Label, Non-Randomized, Phase 1b,2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 Anti-Nkg2a Antibody As A Part of Combination Therapy in Participants With Locally Advanced and Unresectable Or Metastatic Msi-H,Dmmr Gastroesophageal Junction ,Gastric Cancer · 2025 | Their institution | $24,840 |
| Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Vorasidenib in Subjects With Recurrent, Non-Enhancing, Low-Grade Glioma With An Idh1 Or Idh2 Mutation · 2020 | Their institution | $24,672 |
| Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Vorasidenib in Subjects With Recurrent, Non-Enhancing, Low-Grade Glioma With An Idh1 Or Idh2 Mutation · 2021 | Their institution | $22,350 |
| Servier BioInnovation · Study of Orally Administered Ag-881 in Patients With Advanced Solid Tumors, Including Gliomas, With An Idh1 and/Or Idh2 Mutation · 2024 | Their institution | $15,846 |
| AstraZeneca Pharmaceuticals LP · Medi4736 Ph 2 Ludwig Temozolom. Combo Gbm · 2019 | Their institution | $12,798 |
| Servier BioInnovation · Study of Orally Administered Ag-881 in Patients With Advanced Solid Tumors, Including Gliomas, With An Idh1 and/Or Idh2 Mutation · 2025 | Their institution | $12,768 |
| Agios Pharmaceuticals, Inc. · A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-881 in Patients With Advanced Hematologic Malignancies With An Idh1 and/Or Idh2 Mutation · 2020 | Their institution | $7,709 |
| SERVIER AFFAIRES MEDICALES · Study of Vorasidenib (Ag-881) in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation (Indigo) · 2023 | This clinician | $7,095 |
| Agios Pharmaceuticals, Inc. · 2019 | Their institution | $3,083 |
| Servier BioInnovation · Study of Ag-120 and Ag-881 in Subjects With Low Grade Glioma · 2024 | This clinician | $1,932 |
| Servier BioInnovation · Phase 1 Astrocytoma Study Which Is A Study Looking at the Combination of Vorasidenib and Pembrolizumab · 2023 | This clinician | $1,567 |
| Servier BioInnovation · Phase 1 Astrocytoma Study Which Is A Study Looking at the Combination of Vorasidenib and Pembrolizumab · 2024 | This clinician | $1,374 |
| Servier BioInnovation · Study of Orally Administered Ag-881 in Patients With Advanced Solid Tumors, Including Gliomas, With An Idh1 and/Or Idh2 Mutation · 2023 | Their institution | $576 |
| AstraZeneca Pharmaceuticals LP · Medi4736 Ph 2 Ludwig Temozolom. Combo Gbm · 2020 | Their institution | $275 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972776623
- Licence
- CA A85636, NY 240411California A85636: Current · expires 2027-08-31
- Trained
- University of California, San Francisco School of Medicine, 2002 · 24 years ago
- Group
- UCSF Medical Group Business Services · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 400 Parnassus Ave, Room A-808, San Francisco, CA, 94143
- NPI first listed
- 2008-04-02
- NPI last updated
- 2008-04-02
This is when the NPI record was last certified, not a medical board exam.